China Biotech Services Holdings Limited provided consolidated earnings guidance for the year ended 31 December 2023. For the period, Group expected to record a net loss attributable to the owners of the Company of approximately HKD 90,000,000. In contrast to the Loss, the Group recorded a net profit attributable to the owners of the Company of approximately HKD 258,087,000 for the corresponding period in 2022.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.285 HKD | +1.79% | +7.55% | -62.99% |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-62.99% | 35.07M | |
-14.92% | 84.68B | |
+13.30% | 81.12B | |
+11.62% | 29.4B | |
-12.71% | 16.73B | |
-3.06% | 16.36B | |
-2.63% | 14.92B | |
-31.75% | 11.77B | |
-1.42% | 11.72B | |
+27.44% | 11.71B |
- Stock Market
- Equities
- 8037 Stock
- News China Biotech Services Holdings Limited
- China Biotech Services Holdings Limited Provides Consolidated Earnings Guidance for the Year Ended 31 December 2023